PT96567A - Processo para a preparacao de agentes veiculares farmaceuticos sob a forma de finas particulas secas para aerossois - Google Patents

Processo para a preparacao de agentes veiculares farmaceuticos sob a forma de finas particulas secas para aerossois Download PDF

Info

Publication number
PT96567A
PT96567A PT96567A PT9656791A PT96567A PT 96567 A PT96567 A PT 96567A PT 96567 A PT96567 A PT 96567A PT 9656791 A PT9656791 A PT 9656791A PT 96567 A PT96567 A PT 96567A
Authority
PT
Portugal
Prior art keywords
process according
pharmacological agent
dry powder
particulate
group
Prior art date
Application number
PT96567A
Other languages
English (en)
Inventor
David Ganderton
Nuha Mohammed Kassem
Original Assignee
Nat Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Res Dev filed Critical Nat Res Dev
Publication of PT96567A publication Critical patent/PT96567A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (3)

  1. R ϋ I ¥ I W D I 0 A C Q 1 S 1"· "* Processo para a preparação de agentes veiculares farmacêuticos sob a forma de finas partículas para aerossóis» caracterizado pelo facto de compreender a precipitação do agente veicular a partir duma solução aquosa saturada por adição de» pelo menos* um volume igual a um dissolvente inorgânico imiscível com água e uma quantidade de um dissolvente miscível com água e com o dissolvente imiscível com água* o qual ét pelo menos» igual a 5$ em volume do volume da solução aquosa· 2®. - Processo de acordo com a reivindicação 1, carácter izado pelo facto de se escolher o dissolvente imiscível com água do grupo formado por hexano, clorofórmio* cielo-he-xano e tolueno. 3®. - Processo de acordo cosi as reivindicações 1 ou 2» earacterisado pelo facto de se escolher o dissolvente mis-cível com água do grupo formado por acetona, etaaol, propa-nol, butanol e acetonitrilo. 4-* - Processo de acordo com qualquer das reivindicações anteriores, earaeterizado pelo facto de se obter um agente veicular em partículas apropriado para aplicação em composições para inalação sob a forma de pó seco tendo uma granulometria compreendida entre 5*0 e 1000 micrómetroa e uma rugosidade inferior a 1*75* 5§« - Processo de acordo com a reivindicação 4, caracterizado polo facto de o agente veicular ser um açúcar cristalino em partículas, — 16
  2. 62. - Processo de acordo com a reivindicação 5» ca-racterisado pelo facto áe se escolher o referido açúcar cristalino do grupo constituído por glucose, frutos©* manitol, sacarose e lactose* 7a* - Processo de acordo com a reivindicação 6, ca-racterizado pelo facto de o mencionado açúcar cristalino ser lactose. 8a* - Processo de acordo com qualquer das reivindicações 4 a 7» caracterizado pelo facto de as referidas partículas terem uma granulometria média compreendida entre 30 e 250 micrómetros. 9®* - Processo de acordo eo·; qualouer das reivindicações anteriores, caracterizado pelo facto de as citadas partículas tere® uma rugosidade máxima igual a 1,5. 105* - Processo.para a preparação de composições farmacêuticas para inalação sob a forma de pó seco, caracte-riçado pelo facto de se misturar pelo menos um agente farmacológico como ingrediente aetivo com um excipiente veicular em partículas áe acordo com qualquer das reivindicações anteriores. 11®. - Processo de acordo com a reivindicação 10, caracterizado pelo facto de o mencionado excipiente compreender pelo menos 30$ em peso do agente veicular em partículas. 122* - Processo de acordo com a reivindicação 11, caracterizado pelo facto de o referido excipiente ser constituído essencialmente pelo agente veicular em partículas*
  3. 132. - Processo de acordo com qualquer das reivindi- %
    Ί 1ψ Λ.
    :^λ. cações 10 a 12, caracterizado pelo facto de a composição compreender 0,1 a 50y' em peso de agente farmacológico. 14§. - processo de acordo com qualquer das reivindicações 10 a 13, caracterizado pelo facto de 0 mencionado agen te farmacológico ser um sólido em partículas tendo uma granu-lometria média compreendida entre 0*1 e 10 micrometros. 15-· - Processo âe acordo com qualquer das reivindicações 10 a 14» caracterizado pelo facto de o agente farmacológico ser um agonista, um esteróide ou . cromoglicato de sódio. 16®. - Processo de acordo com qualquer das reivindicações 10 a 14> caracterizado pelo facto de o citado agente farmacológico ser um péptido. 17?.. - Processo de acordo cos a reivindicação 16, caracterizado pelo facto de se escolher o referido agente farmacológico do grupo que compreende insulina e hormonas de crescimento, como análogos de adrenoeorticotrofina (AGTIl) e de normona luteinisante-normona de libertação (LHPJl). 18®. - Processo de acordo com qualquer das reivindicações 10 a 14, caracterizado pelo facto de o agente farmacológico ser um agente antibacteriano. 19?. - Proeesso de acordo eom a reivindicação 18, caracterizado pelo facto de o agente antibacteriano ser p, P'-(pentametilenodioxi)-dibenzamidina (pentamidina). 205* - Inalador para pós secos* caracterízado pelo facto de conter uma composição farmacêutica para inalação com a forma de pó seco de acordo com qualquer das reivindicações anteriores. Lisboa, 24 de Janeiro de 1991 0 Açoute Oficial da Propriedade Industrial
    líísdírlsf ás £fe iteráto Agente Ofioial de Propriedade Indoatrial R„ Castilho, 201-3. £.-1000 LISBOA Telefe. 65 13 39-654613
PT96567A 1990-01-24 1991-01-24 Processo para a preparacao de agentes veiculares farmaceuticos sob a forma de finas particulas secas para aerossois PT96567A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909001635A GB9001635D0 (en) 1990-01-24 1990-01-24 Aerosol carriers

Publications (1)

Publication Number Publication Date
PT96567A true PT96567A (pt) 1991-10-15

Family

ID=10669832

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96567A PT96567A (pt) 1990-01-24 1991-01-24 Processo para a preparacao de agentes veiculares farmaceuticos sob a forma de finas particulas secas para aerossois

Country Status (15)

Country Link
US (1) US5254330A (pt)
EP (1) EP0464171B1 (pt)
JP (1) JP3100626B2 (pt)
KR (1) KR920700623A (pt)
AT (1) ATE98487T1 (pt)
AU (1) AU635616B2 (pt)
CA (1) CA2049302C (pt)
DE (1) DE69100792T2 (pt)
FI (1) FI914460A0 (pt)
GB (2) GB9001635D0 (pt)
HU (1) HUT59821A (pt)
IE (1) IE910222A1 (pt)
NO (1) NO913731L (pt)
PT (1) PT96567A (pt)
WO (1) WO1991011179A1 (pt)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE77947T1 (de) * 1987-04-09 1992-07-15 Fisons Plc Pentamidin enthaltende pharmazeutische zusammensetzungen.
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
ATE145819T1 (de) * 1992-03-10 1996-12-15 Fisons Plc Inhalierbare arzneimittel
ES2177544T3 (es) * 1992-06-12 2002-12-16 Teijin Ltd Polvo ultrafinno para inhalar y metodo para su preparacion.
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
AUPM411494A0 (en) * 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
CZ295827B6 (cs) 1994-03-07 2005-11-16 Nektar Therapeutics Způsob aerosolizace dávky inzulinu, inzulinový přípravek a jeho použití
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5536249A (en) * 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5641510A (en) * 1994-07-01 1997-06-24 Genentech, Inc. Method for treating capsules used for drug storage
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
AU703532B2 (en) * 1994-12-22 1999-03-25 Astra Aktiebolag Therapeutic preparation for inhalation containing parathyroid hormone, PTH
PL320856A1 (en) 1994-12-22 1997-11-10 Astra Ab Aerosol drug preparations
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
AU1860697A (en) * 1995-09-08 1997-07-28 Visionary Medical Products Corporation Pen-type injector drive mechanism
FR2742164B1 (fr) * 1995-12-11 1999-01-29 Beghin Say Eridania Sucre microcristallin : composition et methode d'obtention
US5699789A (en) * 1996-03-11 1997-12-23 Hendricks; Mark R. Dry powder inhaler
AU6014098A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems Aerosolized hydrophobic drug
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
EP0876814A1 (en) * 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
SE9701956D0 (sv) 1997-05-23 1997-05-23 Astra Ab New composition of matter
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
PL340736A1 (en) * 1997-12-03 2001-02-26 Fujisawa Pharmaceutical Co Drug in the form of soft granules and method of obtaining same
GB9806477D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved crystals
US6489183B1 (en) * 1998-07-17 2002-12-03 Micron Technology, Inc. Method of manufacturing a taped semiconductor device
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
CZ303154B6 (cs) 1998-11-13 2012-05-09 Jagotec Ag Suchá prášková formulace k inhalaci obsahující stearát horecnatý
AU1786199A (en) * 1998-12-11 2000-07-03 Pharmachemie B.V. Pharmaceutical preparation for inhalation of an opioid
DE60018395T2 (de) 1999-04-21 2006-04-13 1355540 Ontario Inc., Concord Methacoline oder histamine formulierungen zur feststellung von asthma
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
JP4713798B2 (ja) 1999-06-29 2011-06-29 マンカインド コーポレイション ペプチドおよびタンパク質の薬学的因子の精製および安定化
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ITMI991582A1 (it) * 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
AU5523701A (en) * 2000-04-06 2001-10-23 Wayne P Franco Methods of using growth factors for treating heart disease
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
WO2002007705A1 (en) * 2000-07-20 2002-01-31 Campina B.V. Carrier material for dry powder inhalation
CA2425035A1 (en) * 2000-10-09 2002-04-18 3M Innovative Properties Company Medicinal aerosol formulations
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
GB0030074D0 (en) * 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
DE10141376A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern
DE10141377A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
JP2005506323A (ja) * 2001-09-05 2005-03-03 ベクトゥラ・リミテッド 経口送達用機能性散剤
BR0214279A (pt) * 2001-11-19 2005-12-20 Becton Dickinson Co Composições farmacêuticas em forma particulada
SI1458360T1 (sl) 2001-12-19 2011-08-31 Novartis Ag Pulmonalno dajanje aminoglikozidov
EP1490031A1 (en) * 2002-03-07 2004-12-29 Vectura Limited Fast melt multiparticulate formulations for oral delivery
EP1494732B1 (en) 2002-03-20 2008-01-30 MannKind Corporation Inhalation apparatus
EP1494652A1 (en) * 2002-04-12 2005-01-12 Campina Nederland Holding B.V. Excipient for use in dry powder inhalation preparations
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
WO2003094890A1 (en) * 2002-05-07 2003-11-20 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
US20040014662A1 (en) * 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
GB0210527D0 (en) * 2002-05-08 2002-06-19 Univ Bath Process for the treatment of particles for use in pharmaceutical formulations
EP1643973A1 (en) 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
CA2539033C (en) * 2003-09-12 2013-03-05 Neuronova Ab Treatment of disease or injury of the nervous system with fty720
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070189979A1 (en) * 2003-09-18 2007-08-16 Norton Healthcare Limited T/A Ivax Pharmaceuticals Particles
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
EP2708225B1 (en) 2004-04-23 2018-12-26 CyDex Pharmaceuticals, Inc. DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin
KR101273120B1 (ko) 2004-08-20 2013-06-13 맨카인드 코포레이션 다이케토피페라진 합성의 촉매 작용
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
JP2008529773A (ja) * 2005-02-10 2008-08-07 グラクソ グループ リミテッド 医薬製剤に使用するためのラクトース粒子の結晶化方法
ES2613391T3 (es) 2005-02-10 2017-05-24 Glaxo Group Limited Procedimientos de fabricación de lactosa que utilizan técnicas de preclasificación y formulaciones farmacéuticas formadas a partir de la misma
AU2006278571B2 (en) * 2005-08-05 2011-11-24 3M Innovative Properties Company Compositions exhibiting improved flowability
IN2014DN09128A (pt) 2005-09-14 2015-07-10 Mannkind Corp
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
BRPI0707991B8 (pt) 2006-02-22 2021-05-25 Mannkind Corp métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル, インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
EP2049086A2 (en) * 2006-08-09 2009-04-22 Glaxo Group Limited Process for manufacturing lactose
PL2425820T3 (pl) 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CN109568740B (zh) 2008-06-13 2022-05-27 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2904623T3 (es) 2008-06-20 2022-04-05 Mannkind Corp Aparato interactivo para establecer un perfil en tiempo real de esfuerzos de inhalación
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
EP2191821A1 (en) 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
KR20130117755A (ko) 2010-06-21 2013-10-28 맨카인드 코포레이션 건조 분말 약물 운반 시스템 및 방법
TR201007250A2 (tr) 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2729480A4 (en) * 2011-07-08 2014-12-31 Pfizer Ltd PROCESS FOR THE PREPARATION OF FLUTICASONE PROPIONATE, FORM 1
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
ES2754388T3 (es) 2013-03-15 2020-04-17 Mannkind Corp Composiciones y métodos de dicetopiperazina microcristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE292149C (pt) *
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
SE7812207L (sv) * 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
US4349542A (en) * 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
GB2077100B (en) * 1980-04-30 1985-04-24 Fisons Ltd Pharmaceutical compositions containing cromoglycates
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
EP0248051A1 (en) * 1985-11-29 1987-12-09 FISONS plc Pharmaceutical composition including sodium cromoglycate
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system

Also Published As

Publication number Publication date
US5254330A (en) 1993-10-19
NO913731D0 (no) 1991-09-23
NO913731L (no) 1991-11-21
AU635616B2 (en) 1993-03-25
JP3100626B2 (ja) 2000-10-16
FI914460A0 (fi) 1991-09-23
EP0464171B1 (en) 1993-12-15
KR920700623A (ko) 1992-08-10
EP0464171A1 (en) 1992-01-08
GB2240337A (en) 1991-07-31
CA2049302A1 (en) 1991-07-25
CA2049302C (en) 2001-05-29
DE69100792D1 (de) 1994-01-27
HU913284D0 (en) 1992-01-28
GB2240337B (en) 1993-02-24
WO1991011179A1 (en) 1991-08-08
AU7155991A (en) 1991-08-21
IE910222A1 (en) 1991-07-31
DE69100792T2 (de) 1994-04-14
HUT59821A (en) 1992-07-28
GB9101551D0 (en) 1991-03-06
ATE98487T1 (de) 1994-01-15
JPH04504427A (ja) 1992-08-06
GB9001635D0 (en) 1990-03-21

Similar Documents

Publication Publication Date Title
PT96567A (pt) Processo para a preparacao de agentes veiculares farmaceuticos sob a forma de finas particulas secas para aerossois
DE60024811T3 (de) Poröse arzneistoffmatrizen und deren herstellungsverfahren
CA2162993A1 (en) Solid fat nanoemulsions as drug delivery vehicles
EP2011484A3 (en) Use of a dry powder composition of formoterol in the treatment of chronic obstructive pulmonary disease
JP2018537437A5 (pt)
Chauhan et al. Phytosomes: a potential phyto-phospholipid carriers for herbal drug delivery
CA2533887A1 (en) Injectable, oral, or topical sustained release pharmaceutical formulations
FI3125875T3 (fi) Inhaloitava rapamysiiniformulaatio ikäsidonnaisten tilojen hoitoon
JP2006503865A (ja) 吸入のための徐放性の多孔性微粒子
KR20070054644A (ko) 미립자 제형으로 흡입된 일로프로스트에 의한 폐고혈압의치료
US20040176391A1 (en) Aerosolizable pharmaceutical formulation for fungal infection therapy
WO2002101412A3 (en) Spray freeze-dried compositions
BR0016879A (pt) Métodos para transferência de interleucina-2 por via pulmonar
SI2600830T1 (en) A dry powder formulation comprising a phosphodiesterase inhibitor
KR0147852B1 (ko) 가역적 폐색성 기도 질환 치료용 매크롤라이드
CA2591767C (en) Solid lipidic particles as pharmaceutically acceptable fillers or carriers for inhalation
RU2004130438A (ru) Сухая порошковая композиция для ингаляции
MXPA06000243A (es) Formulacion farmaceutica liofilizada estable de tetrodotoxina.
BR0012444A (pt) Composições de pó seco
ATE221372T1 (de) Pharmazeutische zubereitung mit schneller freisetzung
KR900013969A (ko) 지루를 감소시키는 약학 조성물의 제조에 있어서 5'-데옥시-5'-메틸티오아데노신, s-아데노실메티오닌 및 이들의 염의 용도 및 이와 관련된 약학 조성물
ITMI990454A1 (it) Composizioni a rilascio controllato di betaistina
AU2006200277B2 (en) Perforated microparticles and methods of use
PT94372A (pt) Processo de producao de um sistema de distribuicao de droga em suspensao em liquido nao aquoso, a base de, entre outros, clorazepato dipotassico
US20030003057A1 (en) Methods for administering leuprolide by inhalation

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19910618

FC3A Refusal

Effective date: 19970429